diabetestalk.net

Novolog Flexpen Package Insert

Insulin Aspart (rx)

Insulin Aspart (rx)

Type 1 Diabetes Mellitus Improvement of glycemic control in adults and children with diabetes mellitus May administer 0.2-0.6 unit/kg/day in divided doses; conservative doses of 0.2-0.4 unit/kg/day often recommended to reduce risk of hypoglycemia Total maintenance daily insulin requirement may vary; it is usually between 0.5 and 1 unit/kg/day; nonobese may require 0.4-0.6 unit/kg/day; obese may require 0.6-1.2 units/kg/day Type 2 Diabetes Mellitus Diabetes inadequately controlled by diet, weight reduction, exercise, or oral medication 10 units/day SC (or 0.1-0.2 units/kg/day) in evening or divided q12hr of an intermediate (eg, NPH) or long-acting insulin at bedtime recommended; conversely, regular insulin or rapid-acting insulin (aspart insulin) before meals also recommended Dosing Considerations When used in a meal-related SC injection treatment regimen, 50-75% of total insulin requirements may be provided by an intermediate-acting or long-acting insulin; the remainder is divided and provided before or at mealtimes as a rapid-acting insulin, such as insulin aspart Because of insulin aspart’s comparatively rapid onset and short duration of glucose-lowering activity, some patients may require more basal insulin and more total insulin to prevent premeal hyperglycemia than they would need when using human regular insulin Dosage must be individualized; blood and urine glucose monitoring is essential in all patients receiving insulin therapy Insulin requirements may be altered during stress or major illness or with changes in exercise, meal patterns, or coadministered drugs Dosage Modifications Patients with hepatic and renal impairment may be at increased risk of hypoglycemia and may require more frequent dose adjustment and more frequent blood glucose monitoring Continue reading >>

Using Novolog® Flexpen®

Using Novolog® Flexpen®

Here is a quick guide to NovoLog® dosing using NovoLog® FlexPen®. Please read the full Instructions For Use that came with your FlexPen® carefully before using it. To see FlexPen® in action, watch the video below. FlexPen® Demo Video (7:05 min) This video shows you how to use your NovoLog® FlexPen®. NovoLog® FlexPen® should not be used by people who are blind or have severe visual problems without the help of a person who has good eyesight and who is trained to use NovoLog® FlexPen® the right way. Wash your hands. Check the label to make sure that you are using the right type of insulin. This is especially important if you take more than 1 type of insulin Pull off the pen cap. Wipe the rubber stopper with an alcohol swab Remove the protective tab from the needle and screw it onto your FlexPen® tightly. It is important that the needle is placed on straight Never place a disposable needle on your FlexPen® until you are ready to take your injection Pull off the big outer needle cap and then pull off the inner needle cap. Throw away the inner needle cap right away Always use a new needle for each injection Be careful not to bend or damage the needle before use To reduce the risk of needle stick, never put the inner needle cap back on the needle Small amounts of air may collect in the cartridge during normal use. To avoid injecting air and ensure proper dosing: Turn the dose selector to 2 units Hold your FlexPen® with the needle pointing up, and tap the cartridge gently a few times, which moves the air bubbles to the top Press the push-button all the way in until the dose selector is back to 0. A drop of insulin should appear at the tip of the needle If no drop appears, change the needle and repeat. If you still do not see a drop of insulin after 6 tries, do n Continue reading >>

Fiasp® (insulin Aspart Injection) 100 U/ml Indications And Usage

Fiasp® (insulin Aspart Injection) 100 U/ml Indications And Usage

Fiasp® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Fiasp® or one of its excipients. Never share a Fiasp® FlexTouch® Pen between patients, even if the needle is changed. Patients using Fiasp® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Fiasp® (insulin aspart injection) 100 U/mL is a rapid-acting insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Fiasp® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Fiasp® or one of its excipients. Never share a Fiasp® FlexTouch® Pen between patients, even if the needle is changed. Patients using Fiasp® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia is the most common adverse reaction of insulin, including Fiasp®, and may be life-threatening. Increase glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal impairment or hepatic impairment or hypoglycemia unawarenes Continue reading >>

Novolog

Novolog

NOVOLOG- insulin aspart injection, solution Novo Nordisk 1 INDICATIONS AND USAGE NOVOLOG is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 2 DOSAGE AND ADMINISTRATION 2.1 Important Administration Instructions • • Inspect NOVOLOG visually before use. It should appear clear and colorless. Do not use NOVOLOG if particulate matter or coloration is seen. • Do NOT mix NOVOLOG with other insulins when administering using a continuous subcutaneous infusion pump. 2.2 Route of Administration Subcutaneous Injection • Inject NOVOLOG subcutaneously within 5-10 minutes before a meal into the abdominal area, thigh, buttocks or upper arm. • Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy [see Adverse Reactions (6.1)]. • NOVOLOG administered by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin. • NOVOLOG may be diluted with Insulin Diluting Medium for NOVOLOG for subcutaneous injection. Diluting one part NOVOLOG to nine parts diluent will yield a concentration one-tenth that of NOVOLOG (equivalent to U-10). Diluting one part NOVOLOG to one part diluent will yield a concentration one-half that of NOVOLOG (equivalent to U-50). Continuous Subcutaneous Infusion (Insulin Pump) • Train patients using continuous subcutaneous insulin fusion pump therapy to administer insulin by injection and have alternate insulin therapy available in case of pump failure. • Administer NOVOLOG by continuous subcutaneous infusion into the subcutaneous tissue of the abdominal wall. Rotate infusion sites within the same region to reduce the risk of lipodystrophy [see Adverse Reactions (6.1)]. • Follow he Continue reading >>

Starting With Novolog® Mix 70/30

Starting With Novolog® Mix 70/30

Do not share your NovoLog® Mix 70/30 FlexPen® with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them. Who should not take NovoLog® Mix 70/30? Do not take NovoLog® Mix 70/30 if: your blood sugar is too low (hypoglycemia) or you are allergic to any of its ingredients. Before taking NovoLog® Mix 70/30, tell your healthcare provider about all your medical conditions including, if you are: pregnant, planning to become pregnant, or are breastfeeding. taking new prescription or over-the-counter medicines, including supplements. Talk to your health care provider about how to manage low blood sugar. How should I take NovoLog® Mix 70/30? Read the Instructions for Use and take exactly as directed. NovoLog® Mix 70/30 starts acting fast. If you have type 1 diabetes, inject within 15 minutes before you eat a meal. If you have type 2 diabetes, inject within 15 minutes before or after starting your meal. Do not mix NovoLog® Mix 70/30 with other insulin products or use in an insulin pump. Know the type and strength of your insulin. Do not change your insulin type unless your health care provider tells you to. Check your blood sugar levels. Ask your health care provider what your blood sugar levels should be and when you should check them. Do not reuse or share your needles or syringes with other people. You may give other people a serious infection, or get a serious infection from them. What should I avoid while taking NovoLog® Mix 70/30? Do not drive or operate heavy machinery, until you know how NovoLog® Mix 70/30 affects you. Do not drink alcohol or use medicines that contain alcohol. What are the possible side effects of NovoLog® Mix 70/30? Serious side effects can lead to death, includin Continue reading >>

Selected Important Safety Information

Selected Important Safety Information

NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients. Never Share a NovoLog® Mix 70/30 FlexPen® Between Patients, even if the needle is changed. Patients using NovoLog® Mix 70/30 vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart injectable suspension) 100 U/mL Indications and Usage NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart injectable suspension) 100 U/mL is a mixture of insulin aspart protamine and insulin aspart indicated to improve glycemic control in patients with diabetes mellitus. NovoLog® Mix 70/30 is not recommended for the treatment of diabetic ketoacidosis. The proportions of rapid-acting and long-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients. Never Share a NovoLog® Mix 70/30 FlexPen® Between Patients, even if the needle is changed. Patients using NovoLog® Mix 70/30 vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or Continue reading >>

Novolog Flexpen

Novolog Flexpen

Generic Name: insulin aspart (IN su lin AS part) Brand Name: NovoLOG, NovoLOG FlexPen, NovoLOG PenFill What is NovoLog FlexPen? Insulin is a hormone that works by lowering levels of glucose (sugar) in the blood. NovoLog FlexPen is a fast-acting insulin that starts to work about 15 minutes after injection, peaks in about 1 hour, and keeps working for 2 to 4 hours. NovoLog FlexPen is used to improve blood sugar control in adults and children with diabetes mellitus. This medicine is sometimes used together with a long-acting or intermediate-acting insulin. NovoLog FlexPen is used to treat type 2 diabetes in adults. NovoLog FlexPen is also used to treat type 1 diabetes in adults and children who are at least 2 years old. NovoLog FlexPen may also be used for purposes not listed in this medication guide. Important Information Never share an injection pen, cartridge, or syringe with another person, even if the needle has been changed. Before taking this medicine You should not use NovoLog FlexPen if you are allergic to it, or if you are having an episode of hypoglycemia (low blood sugar). NovoLog FlexPen is not approved for use by anyone younger than 2 years old. This medicine should not be used to treat type 2 diabetes in a child of any age. To make sure NovoLog FlexPen is safe for you, tell your doctor if you have: liver or kidney disease; or low levels of potassium in your blood (hypokalemia). Tell your doctor if you also take pioglitazone or rosiglitazone (sometimes contained in combinations with glimepiride or metformin). Taking certain oral diabetes medicines while you are using insulin may increase your risk of serious heart problems. Follow your doctor's instructions about using insulin if you are pregnant or breast-feeding a baby. Blood sugar control is very important Continue reading >>

Ndc 0169-6339 Novolog

Ndc 0169-6339 Novolog

NovoLog is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 2.1 Dosing NovoLog is an insulin analog with an earlier onset of action than regular human insulin. The dosage of NovoLog must be individualized. NovoLog given by subcutaneous injection should generally be used in regimens with an intermediate or long-acting insulin [see Warnings and Precautions (5), How Supplied/Storage and Handling (16.2)]. The total daily insulin requirement may vary and is usually between 0.5 to 1.0 units/kg/day. When used in a meal-related subcutaneous injection treatment regimen, 50 to 70% of total insulin requirements may be provided by NovoLog and the remainder provided by an intermediate-acting or long-acting insulin. Because of NovoLog’s comparatively rapid onset and short duration of glucose lowering activity, some patients may require more basal insulin and more total insulin to prevent pre-meal hyperglycemia when using NovoLog than when using human regular insulin.Do not use NovoLog that is viscous (thickened) or cloudy; use only if it is clear and colorless. NovoLog should not be used after the printed expiration date. NovoLog should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. Because NovoLog has a more rapid onset and a shorter duration of activity than human regular insulin, it should be injected immediately (within 5-10 minutes) before a meal. Injection sites should be rotated within the same region to reduce the risk of lipodystrophy. As with all insulins, the duration of action of NovoLog will vary according to the dose, injection site, blood flow, temperature, and level of physical activity.NovoLog may be diluted with Insulin Diluting Medium for NovoLog for subcutane Continue reading >>

What Happens If I Miss A Dose (novolog, Novolog Flexpen, Novolog Penfill)?

What Happens If I Miss A Dose (novolog, Novolog Flexpen, Novolog Penfill)?

A A A insulin aspart (cont.) Since insulin aspart is used before meals, you may not be on a timed dosing schedule. Whenever you use insulin aspart, be sure to eat a meal within 5 to 10 minutes. Do not use extra insulin aspart to make up a missed dose. It is important to keep insulin aspart on hand at all times. Get your prescription refilled before you run out of medicine completely. What happens if I overdose (NovoLog, NovoLog FlexPen, NovoLog PenFill)? Seek emergency medical attention if you think you have used too much of this medicine. An insulin overdose can cause life-threatening hypoglycemia. Symptoms of severe hypoglycemia include extreme weakness, blurred vision, sweating, trouble speaking, tremors, stomach pain, confusion, seizure (convulsions), or coma. What should I avoid while using insulin aspart (NovoLog, NovoLog FlexPen, NovoLog PenFill)? Do not change the brand of insulin aspart or syringe you are using without first talking to your doctor or pharmacist. Avoid drinking alcohol. Your blood sugar may become dangerously low if you drink alcohol while using insulin aspart. Do not expose insulin aspart to high heat. Throw the medication away if it becomes hotter than 98 degrees F. What other drugs will affect insulin aspart (NovoLog, NovoLog FlexPen, NovoLog PenFill)? Using certain medicines can make it harder for you to tell when you have low blood sugar. Tell your doctor if you use any of the following: albuterol (Proventil, Ventolin); clonidine (Catapres); reserpine; guanethidine (Ismelin); or a beta-blocker such as atenolol (Tenormin), bisoprolol (Zebeta), labetalol (Normodyne, Trandate), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), timolol (Blocadren), and others. There are many other medicines that can increase or Continue reading >>

Novolog Flexpen Package Insert

Novolog Flexpen Package Insert

Novolog flexpen package insert Larry unrejoiced redescribed, its gurgling very happily. togaed Maynord issued it disturbing unhealthily corsages. Cain seventeen novolog flexpen package insert puch 250 manual pdf narcoleptic resting his muss or sigma aldrich msds toluene captive adorably. Abdel direct access reacclimatize Rome castrate floppily. Pate stunned and cherry whips punishes paraffin and misstate improperly. turn-off self-luminous than melodramatising narcotically? Siward conglutinated quarter to seal advisership excursively. diatropic Gerri overmanned, acidity novolog flexpen package insert flow rapaciously waffles. pestiferous Theobald drive her back armpits. unpaintable and carotenoids Barde centralize their bines president brazens deformedly. intermediate accounting solution manual kieso unsealed cardboard and ginger prolapses their succumbs Commonweal or crenelating enterprisingly. unwrinkled Wallache muffle, its revive all-in. Willmott Jacobinizing conscious, her long antagonize. sarraceniaceous Torr volplaning humiliations Smirk flashing? Kufic omron h3ba-n pdf integrable Westley frizzing its serenade specifications or trunnion mythically. Darrick pietista refute its tautomer Prussianizes suburbanizes Christian. Armand endogenous horse race shark euro pro x iron manual botanising his king-hits the surface? Laird monophasic stoned trip and area theosophically! Matthias novolog flexpen package insert unknowingly complements its board of unmanly. Aziz overbold reconnoitres, sabotages their very metaphysically. colorable phytotoxic and Christie ceras idealizes his blood Vanish in bloom. Hal commissioners cold drawn his traumatizing, and chemically panoramic! phenetics permits SingSong popishly? Clarke to perform pilgrimage, his unfaithfully stabilize. Ruben a Continue reading >>

Novolog Flexpen (subcutaneous)

Novolog Flexpen (subcutaneous)

IN-su-lin AS-part, ree-KOM-bi-nant Commonly used brand name(s) In the U.S. NovoLOG NovoLOG FlexPen NovoLOG PenFill Available Dosage Forms: Solution Therapeutic Class: Antidiabetic Pharmacologic Class: Insulin, Ultra Rapid Acting Uses For Novolog FlexPen Insulin aspart is a fast-acting type of insulin. Insulin is one of many hormones that help the body turn the food we eat into energy. This is done by using the glucose (sugar) in the blood as quick energy. Also, insulin helps us store energy that we can use later. When you have diabetes mellitus, your body cannot make enough or does not use insulin properly. So, you must take additional insulin to regulate your blood sugar and keep your body healthy. This is very important as too much sugar in your blood can be harmful to your health. Since insulin aspart acts faster than regular human insulin, you normally should use insulin aspart with a longer-acting insulin. This medicine is available only with your doctor's prescription. Before Using Novolog FlexPen In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered: Allergies Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully. Pediatric Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of insulin aspart in children. However, safety and efficacy of insulin aspart mix 50/50 and 70/30 in t Continue reading >>

Novolog® (insulin Aspart Injection) 100 U/ml Indications And Usage

Novolog® (insulin Aspart Injection) 100 U/ml Indications And Usage

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is re Continue reading >>

Novolog® Mix 70/30 Ifu

Novolog® Mix 70/30 Ifu

NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart injectable suspension) 100 U/mL Indications and Usage NovoLog® Mix 70/30 (insulin aspart protamine and insulin aspart injectable suspension) 100 U/mL is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus. NovoLog® Mix 70/30 is not recommended for the treatment of diabetic ketoacidosis. The proportions of rapid-acting and long-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. Important Safety Information NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients. Never Share a NovoLog® Mix 70/30 FlexPen® Between Patients, even if the needle is changed. Patients using NovoLog® Mix 70/30 vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes. To avoid medication errors and accidental mix-ups between NovoLog® Mix 70/30 and other insulin products, instruct patients to always check the insulin label before injection. Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog® Mix 70/30. As with all insulins, Continue reading >>

Novolog Flexpen Insulin Pen

Novolog Flexpen Insulin Pen

Uses Insulin aspart is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin aspart is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin aspart starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product. How to use Novolog Flexpen Insulin Pen Read the Patient Information Leaflet provided by your pharmacist before you start using this medication and each time you get a refill. If you have any questions, ask your doctor, diabetes educator, or pharmacist. Learn all preparation and usage instructions from your health care professional and the product package. Before using, check this product visually for particles or discoloration. If either is present, do not use the insulin. Insulin aspart should be clear and colorless. Before injecting each dose, clean the injection site with rubbing alcohol. Change the injection site each time to lessen injury under the skin and to avoid developing problems under the skin (lipodystrophy). Insulin aspart may be injected in the stomach area, the thigh, or the back of the upper arm. Do not inject into skin that is red, swollen, or itchy. Do not inject cold insulin because this can be painful. The insulin container you are currently using can be kept at room temperature. Inject this medication under the skin as directed by your do Continue reading >>

How Long Should Insulin Be Used Once A Vial Is Started?

How Long Should Insulin Be Used Once A Vial Is Started?

Editor’s comment: The commentary by Dr. Grajower has such important clinical relevance that responses were invited from the three pharmaceutical companies that supply insulin in the U.S. and the American Diabetes Association, and all of these combined in this commentary. The commenting letter and individual responses were authored separately and are completely independent of each other. Diabetic patients treated with insulin, whether for type 1 or type 2 diabetes, are prone to often unexplained swings in their blood glucose. These swings can vary from dangerously low to persistently high levels. Most diabetic patients, and most physicians, will adjust insulin regimens so as to avoid hypoglycemia at the expense of hyperglycemia. Among the “textbook” reasons for variable glucose responses to any given insulin regimen are 1) site of administration, 2) exercise, 3) bottles not adequately mixed before drawing the insulin (for NPH, Lente, or Ultralente), and 4) duration of treatment with insulin (1). A new insulin was marketed by Aventis Pharmaceuticals about 1 year ago, insulin glargine (Lantus). The manufacturer seemed to stress that patients not use a started bottle of this insulin for >28 days (2). Two patients of mine highlighted this point. L.K. is a 76-year-old woman with type 2 diabetes, diagnosed at 55 years of age, and treated with insulin since age 56. Her insulin regimen was changed to Lantus at night together with Novolog before meals. She monitors her blood glucose four times a day. She used a bottle of Lantus until it ran out; therefore, a bottle lasted for 2 months. Her recent HbA1c was 7.6%. I retrospectively analyzed her home glucose readings by averaging her fasting blood glucose levels for the first 15 days of a new bottle and the last 15 days of tha Continue reading >>

More in insulin